Deutsches Krebsforschungszentrum Patent applications |
Patent application number | Title | Published |
20160071623 | CONTOUR COLLIMATOR FOR RADIOTHERAPY - The invention relates to a contour collimator for radiotherapy, comprising a plurality of plate-shaped diaphragm elements provided in a guiding block and movably arranged with respect to one another to form a contour diaphragm for a radiation beam emitted by a radiation source towards the collimator, and at least one drive for moving the diaphragm elements, wherein a drive of its own is associated with each diaphragm element, the drives of a group of diaphragm elements are arranged substantially adjacent to one another, and the drive is a linear motor, wherein each linear motor comprises a linearly movable rod directly fixed to the associated diaphragm element. The invention facilitates a design of a contour collimator with a shape being as compact as possible, and wherein both precise and stable adjustability of the diaphragm elements is achieved without a backlash. In this way improvements to contour collimators are provided. | 03-10-2016 |
20150362489 | RECEPTORS OF RSPO2 AND RSPO3 - The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders. | 12-17-2015 |
20150218203 | MULTIPLE ORTHOGONAL LABELLING OF OLIGONUCLEOTIDES - In summary, the present invention concerns a method for multiple orthogonal labelling of oligonucleotides, preferably RNA or DNA, by simultaneously performing the inverse Diels-Alder reaction (DAinv) and the copper-catalyzed click reaction (CuAAC), wherein the method is employed in a single step by just adding the different reaction components together and incubating the aqueous reaction mixture preferably for one hour at room temperature. In detail, the reaction components are one or more N | 08-06-2015 |
20150206613 | LEAF ASSEMBLY FOR A MULTI-LEAF COLLIMATOR AND MULTI-LEAF COLLIMATOR - The invention relates to a leaf assembly ( | 07-23-2015 |
20150110715 | Double-Labeled Probe for Molecular Imaging and Use Thereof - The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof. | 04-23-2015 |
20150018239 | BIOMARKER SET FOR IDENTIFYING A SEVERE FORM OF CANCER - The present invention relates to a method for differentiating between i) a severe form of cancer and ii) a mild form of cancer, comprising a) determining the amounts of gene product of at least the genes coding for ribosomal protein S6 (RPS6), nucleoside diphosphate kinase (NME/NDKA), and caveolin-1, in a sample from a subject, b) comparing the amounts obtained in step a) to reference amounts, and c) differentiating between a severe form of cancer and a mild form of cancer, wherein an increased amount of products of the genes coding for RPS6 and NME/NDKA and a decreased amount of product of the gene coding for caveolin-1 are indicative of a severe form of cancer. The invention further relates to the use of antibodies specifically recognizing a polypeptide selected from the list consisting of RPS6, NME/NDKA, and caveolin-1, for differentiating between a severe form of cancer and a mild form of cancer. Furthermore, the invention relates to a detection agent specifically recognizing a polypeptide selected from the list consisting of RPS6, NME/NDKA, and caveolin-1, for use in diagnosing, a device and a kit for differentiating between a severe form of cancer and a mild form of cancer. | 01-15-2015 |
20140357510 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-04-2014 |
20140341915 | B7-H6 THERAPEUTICALLY ACTIVE MONOCLONAL ANTIBODY AGAINST B7-H6 POLYPEPTIDE - The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory. | 11-20-2014 |
20140310829 | MODIFIED PARVOVIRUS USEFUL FOR GENE SILENCING - Described are methods for efficiently down regulating the expression of a gene of interest in a cell by use of a modified rodent parvovirus that contains an expressible target specific nucleic acid, preferably an shRNA expression cassette. Also described are cells or organisms comprising said parvovirus. | 10-16-2014 |
20140302026 | MEANS AND METHODS FOR TREATING ANGIOGENESIS-RELATED DISEASES - The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention. | 10-09-2014 |
20140294860 | MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER - The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer. | 10-02-2014 |
20140288349 | THERAPEUTIC DEVICE FOR TREATING A PREDEFINED BODY PART OF A PATIENT WITH RAYS - A therapeutic device ( | 09-25-2014 |
20140235699 | ADENO-PARVOVIRUS CHIMERA WITH ENHANCED ONCOLYTICAL POTENTIAL - Described is a chimerical adenovirus-parvovirus vector characterized in that it comprises the entire parvovirus genome inserted into a adenovirus genome, wherein: (a) the adenovirus genome is characterized by deletion of E1 and E3, and (b) the biological activity of the parvoviral protein NS, preferably NS1, is reduced or eliminated. | 08-21-2014 |
20140205573 | ONCOLYTIC VIROTHERAPY FOR THE THERAPY OF SARCOMA - The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV. | 07-24-2014 |
20140193927 | PREDICTION OF RECURRENCE FOR BLADDER CANCER BY A PROTEIN SIGNATURE IN TISSUE SAMPLES - The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods. | 07-10-2014 |
20140186917 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 07-03-2014 |
20140134703 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 05-15-2014 |
20140097358 | Method and Apparatus for Imaging a Structure Marked with a Fluorescent Dye - In a method for imaging a structure ( | 04-10-2014 |
20130319610 | METHOD FOR APPLYING A FIRST METAL ONTO A SECOND METAL, AN ISOLATOR OR SEMICONDUCTOR SUBSTRATE, AND THE RESPECTIVE BINDING UNITS - The present invention concerns a method for applying a first metal onto a second metal, an isolator or semiconductor substrate by a Diels-Alder reaction, in particular a Diels-Alder reaction with inverse electron demand. The present invention further concerns the binding units L 1960 and F 160. | 12-05-2013 |
20130310545 | Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors - Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin). | 11-21-2013 |
20130303884 | Method and System for 4D Radiological Intervention Guidance (4D-cath) - An imaging method for radiologically guiding an instrument during medical interventions on an object comprising:
| 11-14-2013 |
20130303550 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS - Compounds of formula (IIc); wherein X | 11-14-2013 |
20130296344 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS - Compounds according to the general formula (I) wherein X | 11-07-2013 |
20130266962 | MEANS AND METHODS FOR DIAGNOSING CANCER USING AN ANTIBODY WHICH SPECIFICALLY BINDS TO BRAF V600E - The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies. | 10-10-2013 |
20130224154 | RETARGETING OF RAT PARVOVIRUS H-1PV TO CANCER CELLS THROUGH GENETIC ENGINEERING OF ITS CAPSID - Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy. | 08-29-2013 |
20130209413 | USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs) - Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells. | 08-15-2013 |
20130195884 | NOVEL MODULATORS OF TRAIL SIGNALLING - The present invention relates to an agent for use as a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation, a method of diagnosing or monitoring apoptosis-factor-associated conditions or disorders as well as a method of identifying a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation. Preferably, the invention relates to TRAIL-induced cell death and/or TRAIL-induced apoptosis. Preferably the agents are used to stimulate and/or enable TRAIL-induced cell death or to inhibit TRAIL-induced cell death. The preferable use of the diagnostic tools is to diagnose sensitivity or resistance to TRAIL-induced cell death or induction of sensitivity or resistance to TRAIL-induced cell death by an agent. | 08-01-2013 |
20130189265 | MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY - Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. | 07-25-2013 |
20130149696 | HIGH-THROUGHPUT METHOD FOR DETERMINING THE PRESENCE OF PAPILLOMAVIRUS-NEUTRALIZING ANTIBODIES IN A SAMPLE - The present invention relates to a method for the determination of the presence of PV-neutralizing antibodies in a sample, comprising a) contacting said sample with infectious PV particles comprising a reporter gene, wherein the gene product of said reporter gene is secreted into the growth medium, b) contacting the PV particles from a) with host cells, and c) determining PV-neutralizing antibodies based on the amount of gene product from said reporter gene, wherein, preferably, a lower amount of said gene product as compared to a reference amount is indicative of the presence of PV-neutralizing antibodies. It further relates to a host cell strongly adhering to multi-cluster plates for use in a method for diagnosing anti-PV immunity comprising the method of the present invention. | 06-13-2013 |
20130143204 | DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF - The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease. | 06-06-2013 |
20130116136 | PROBES FOR GENOTYPING LOW-RISK-HPV - The current invention is concerned with a composition comprising at least one probe oligonucleotide each for the nucleotide sequences of the invention, said probe oligonucleotides specifically hybridizing to the sense strand or the antisense strand of said nucleotide sequences. Moreover, the present invention relates to a method for the identification of low-risk HPV types in a sample comprising the steps of a) contacting a sample with an amplification composition allowing amplification of at least one region of the HPV genome specifically hybridizing to at least one of the probe oligonucleotides of the current invention under conditions which allow for the amplification of polynucleotides and b) identifying low-risk HPV genotypes in said sample based on the amplified polynucleotides obtained in step a) by hybridizing the amplified polynucleotides with at least one labelled probe oligonucleotide of the current invention while said amplified polynucleotides are present in the same reaction container. The invention also relates to the use of a composition of the current invention for identifying low-risk HPV hi a sample and to a kit comprising the composition of the invention and/or adopted for carrying out the method of the invention and an instruction manual. | 05-09-2013 |
20130089523 | ADENOVIRUS DERIVED HELPER VIRUS FOR ENHANCING RECOMBINANT PARVOVIRUS PRODUCTION - Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors. | 04-11-2013 |
20130078666 | SCAFFOLD-BASED ORGANOTYPIC CULTURE FOR THE LONG-TERM CULTIVATION OF HUMAN EPIDERMAL STEM CELLS - The present invention relates to organotypic cultures of epidermal cells and the use thereof for the screening of pharmaceutical and cosmetic agents. Specifically, means for the improvement of the long-term stability of such cultures are disclosed. Thus, the present invention contemplates a skin equivalent comprising (a) a dermal equivalent comprising a matrix comprising nonwoven viscose fabric and fibroblasts and (b) keratinocytes. Moreover, the present invention contemplates a method for manufacturing the skin equivalent and a method for screening agents capable of influencing skin, such as a therapeutic or cosmetic agent. | 03-28-2013 |
20130072397 | METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF A TUMOR USING BCAT1 PROTEIN - The present invention relates to methods for the diagnosis of a tumor, in particular a brain tumor, and for the estimation of a prognosis for patients afflicted with such tumor based on the determination of expression of BCAT1 in a patient sample. | 03-21-2013 |
20130058899 | Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. | 03-07-2013 |
20130045884 | MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER - The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods. | 02-21-2013 |
20130029319 | MEANS AND METHODS FOR PREDICTING THE RISK OF MORTALITY OF PATIENTS WITH HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CANCER - The present invention relates to the field of diagnostic measures. In particular, the present invention relates to a method for predicting the risk of mortality in a subject suffering from low viral load HPV (human papillomavirus) positive oropharyngeal squamous cell cancer. The method is based on the determination of the amount of an E6* gene product and the amount an E1̂E4 gene product of HPV in a sample from said subject. Moreover, the method is based on determining the presence of absence of an E1C gene product of HPV. The present invention further relates to a method for predicting the risk of mortality in a subject suffering from HPV (human papillomavirus) positive oropharyngeal squamous cell cancer based on the determination of copy number of HPV per cancer cell. | 01-31-2013 |
20120294856 | COMPOUNDS INHIBITING CD95 SIGNALING FOR THE TREATMENT OF PANCREATIC CANCER - The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament. | 11-22-2012 |
20120264638 | CIRCULATING miRNAs AS NON-INVASIVE MARKERS FOR DIAGNOSIS AND STAGING IN PROSTATE CANCER - The present invention relates to a method for staging prostate cancer in a subject suffering from prostate cancer, said method comprises (a) determining the amount of at least one miRNA selected from the group consisting of miRNA-375, miRNA-141, miRNA-200b, miRNA-516a-3p and miRNA9*, or the amount of a precursor molecule in a sample from said patient and (b) comparing the, thus, determined amount with a reference amount. Moreover, the present invention is concerned with a method for identifying a subject susceptible to prostate cancer therapy and to a method for diagnosing prostate cancer. Further envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention. | 10-18-2012 |
20120263730 | RECEPTORS OF RSPO2 AND RSPO3 - The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders. | 10-18-2012 |
20120212750 | Three-Dimensionally Localizing Light Emitting Molecules of Unknown Orientation and Unknown Z-Position - To the end of three-dimensionally localizing light emitting marker entities of unknown orientation and unknown position in a sample, the light emitted by each single marker entity is imaged in at least two different ways onto at least one detection plane which corresponds to a focal plane ( | 08-23-2012 |
20120202732 | MODIFIED AAV CAPSID POLYPEPTIDES - The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said polypeptide. Further included is an antibody specifically binding to said polypeptide and a medicament comprising said polynucleotide, vector, polypeptide, or antibody. Also contemplated are the use of said polynucleotide, vector, polypeptide, or antibody for the manufacture of a medicament for the treatment of vascular disease and a method for the identification of a compound binding to said polypeptide. | 08-09-2012 |
20120135022 | ASSEMBLY ACTIVATING PROTEIN (AAP) AND ITS USE FOR THE MANUFACTURE OF PARVOVIRUS PARTICLES ESSENTIALLY CONSISTING OF VP3 - The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The present invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use. | 05-31-2012 |
20120104279 | Fluorescence Light Scanning Microscope Having a Birefringent Chromatic Beam Shaping Device - A fluorescence light scanning microscope ( | 05-03-2012 |
20120040334 | Diagnostic Transcript and Splice Patterns of HPV16 in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of said first gene product and the amount of said second gene product. Further envisaged by the present invention is a composition comprising an oligonucleotide mixture. Also envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention. | 02-16-2012 |
20120039912 | RSPONDIN-3 INHIBITION IN BONE DISORDERS - The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption. | 02-16-2012 |
20110318363 | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity - Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes. | 12-29-2011 |
20110300113 | Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro - The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation. | 12-08-2011 |
20110275059 | Diagnostic Transcript and Splice Patterns of HR-HPV in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention. | 11-10-2011 |
20110249311 | Method and Device for Dynamically Shifting a Light Beam with Regard to an Optic Focussing the Light Beam - For dynamically shifting a light beam ( | 10-13-2011 |
20110142811 | MEASLES VIRUS FOR THE ELIMINATION OF UNWANTED CELL POPULATIONS - The present invention concerns recombinant measles virus as a therapeutic, in particular a recombinant measles virus comprising a suicide gene in its genome, a mutated viral hemagglutinin, and a specificity domain specifically recognizing a cancer antigen. Furthermore, it relates to a polynucleotide coding for such a recombinant measles virus and a vector comprising said polynucleotide. The current invention also relates to a method for the manufacture of and a medicament comprising said recombinant measles virus, as well as a method for treating a solid tumor using said recombinant measles virus. | 06-16-2011 |
20110123483 | HMGB1 FOR CANCER TREATMENT - The current invention relates to a method for treating a subject suffering from cancer comprising administering to said subject a therapeutically effective dose of High Mobility Group B1 (HMGB1) protein or of a polynucleotide comprising a coding region for an HMGB1 gene in an expressible form. Moreover, it relates to the combination of said method with other cancer treatment regimens. | 05-26-2011 |
20110033425 | Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 02-10-2011 |
20110020287 | Parvovirus Cancer Therapy and Combination with Chemotherapy - Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine. | 01-27-2011 |
20100276585 | METHOD FOR DETERMINING THE CONCENTRATION OF A MOLECULE - The present invention relates to a method for determining the concentration of a first molecule having a chemical structure, which contains a first peptide sequence comprising: (a) obtaining a sample containing the first molecule, (b) providing a reference sample which contains a second molecule having a certain concentration and chemical structure, which contains a second peptide sequence, wherein the chemical structure of the second molecule only differs from the structure of the first molecule in one or more permutations in the first peptide sequence, (c) combining the reference sample and the sample containing the first molecule, (d) identifying at least one fragment peak in a mass spectrum (MS) of the first molecule and the second molecule, wherein the mass difference of the fragment peaks is only caused by the permutation of the at least two different amino acids, and (e) determining the concentration of the first molecule relative to the certain concentration of the second molecule by comparing of the identified peaks. | 11-04-2010 |
20100232668 | Method, Computer Program And Workstation For Removing Undesirable Objects From A Digital Medical Image - A method of removing undesirable objects such as bones from a digital medical image is disclosed. In the preferred embodiment, the method comprises the steps of generating a symbolic representation of the medical image, wherein said symbolic representation comprises a directed graph comprising vertices and edges, wherein each pixel or voxel of the digital medical image is associated with an edge of the graph, and wherein the root of said directed graph is not located within said undesirable object; electing, by user input, a site located within said undesirable object; determining a path in the symbolic representation, said path including the edge associated with said elected site and propagating towards the root of said directed graph; visualizing the part of the image associated with said determined path; identifying within said visualized part of the image the transition between the undesired object and the remainder of the image; and removing the part of the image associated with the branch of the graph rooted at said transition between the undesired object and the remainder of the image. | 09-16-2010 |
20090242801 | METHOD OF FLUORESCENCE-MICROSCOPICALLY IMAGING A STRUCTURE IN A SAMPLE WITH HIGH THREE-DIMENSIONAL SPATIAL RESOLUTION - For imaging a structure in a sample with three-dimensional spatial resolution, a fluorophore is selected which is transferable by means of an optical transfer signal out of a first into a second photochromic state having specific fluorescence properties, and which displays a return rate back into the first photochromic state. The structure is labeled with the fluorophore. Via a common objective, the sample with the labeled structure is subjected both to the optical transfer signal in a spatially limited transfer-volume, and to an optical excitation signal exciting a portion of the fluorophore being in its second photochromic state for fluorescence in a spatially limited excitation-volume, the transfer-volume and the excitation-volume having a common centre of maximum intensity of the transfer signal and of the excitation signal, and a decrease of intensity of the transfer signal with the distance to the common centre of maximum intensity being substantially stronger than any decrease of the effective return rate of the fluorophore. Fluorescence light emitted by the excited fluorophore is detected. The common centre of maximum intensity is shifted with regard to the sample; and the steps of subjecting and detecting are repeated. | 10-01-2009 |
20090082258 | Means and Methods for Treating Advanced Stage Neuroblastoma - The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases. | 03-26-2009 |
20080298401 | Device and Method for Creating a Spatial Dose Distribution in a Medium Volume - A device and a method for creating a spatial dose distribution in a medium volume ( | 12-04-2008 |
20080234185 | Use of Dmbt1 for Capturing Sulphate and Phosphate Group Exposing Agents - Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1 as a diagnostic for diagnosing the susceptibility of an individual to sulphate or phosphate groups, as well as methods for diagnosis, prophylaxis or treatment of diseases caused by an agent which possesses at least one accessible sulphate and/or at least one accessible phosphate group. | 09-25-2008 |